LYX-34451-72799
4 vaccinations
2 coded responses
24 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 0-4
- ZIP prefix
- 554 / MN
- Registered
- 2022-07-04
- Relationship
- Child or adolescent in my care
- Guardian
- 6AR-31113-07111
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-07-01
Dose 1 — Moderna
-
2022-07-04
Registered in v-safe
- 2022-07-04
- 2022-07-05
- 2022-07-06
- 2022-07-07
- 2022-07-08
- 2022-07-15
- 2022-07-22
-
2022-07-29
Dose 2 — Moderna
- 2022-07-29
-
2022-07-30
Health check-in — days 1–6 daily, dose 2, under 3Feeling: Good · Site: Pain · NoneUnder 3 check-in
- 2022-07-31
- 2022-08-01
- 2022-08-02
- 2022-08-03
- 2022-08-04
- 2022-08-05
- 2022-08-12
- 2022-08-19
- 2022-08-26
- 2022-09-02
- 2022-09-09
-
2022-10-13
Dose 3 — Pfizer-BioNTech
-
2022-10-28
Survey response — 3 months, dose 2, under 3MedDRA: Cough, Exposure to communicable disease, Rhinorrhoea, SARS-CoV-2 test negative — Feeling: FairFree text: Cough, runny nose, exposure to RSV, negative covid home test.MedDRA releases: 2024-11 · check-in free text available
-
2022-12-28
Dose 4 — Moderna
-
2023-01-27
Survey response — 6 months, dose 2, under 3MedDRA: Conjunctivitis, Illness, Nasopharyngitis, Respiratory syncytial virus infection, SARS-CoV-2 test negative — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-01-27
Report sent to call center — 6 months, dose 2, under 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2023-01-30
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2023-03-29
- 2023-06-28
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-07-01 | Moderna | No |
| 2 | 2022-07-29 | Moderna | No |
| 3 | 2022-10-13 | Pfizer-BioNTech | No |
| 4 | 2022-12-28 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2023-01-27 | Successful 2023-01-30 |
Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill |
Free text
Release 12 (Under 3) — 3 months, dose 2, under 3
Symptoms: Cough, runny nose, exposure to RSV, negative covid home test.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Conjunctivitis | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Exposure to communicable disease | · | · | ✓ |
| SD | Illness | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Respiratory syncytial virus infection | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release